tetano
Editor, Senior Moderator
Rheumatology (Oxford)
. 2021 Dec 11;keab886.
doi: 10.1093/rheumatology/keab886. Online ahead of print.
SARS-CoV-2 vaccine in patients with systemic sclerosis: Impact of disease subtype and therapy
Percival Degrava Sampaio-Barros[SUP] 1 [/SUP], Ana Cristina Medeiros-Ribeiro[SUP] 1 [/SUP], Ana Paula Luppino-Assad[SUP] 1 [/SUP], Renata Miossi[SUP] 1 [/SUP], Henrique Carriço da Silva[SUP] 1 [/SUP], Emily F V N Yuki[SUP] 1 [/SUP], Sandra G Pasoto[SUP] 1 [/SUP], Carla G S Saad[SUP] 1 [/SUP], Clóvis A Silva[SUP] 1 2 [/SUP], Léonard V K Kupa[SUP] 1 [/SUP], Giordano B H Deveza[SUP] 1 [/SUP], Tatiana N Pedrosa[SUP] 1 [/SUP], Nádia E Aikawa[SUP] 1 2 [/SUP], Eloisa Bonfá[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: To analyse the safety, immunogenicity and factors affecting antibody response to Severe Acute Respiratory Syndrome-Coronavirus-2(SARS-CoV-2) vaccination in patients with systemic sclerosis (SSc).
Methods: This is a phase 4 prospective study within a larger trial of two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in 51 SSc patients compared with 153 controls. Anti-SARS-CoV-2-IgG and neutralizing antibodies (NAb) were assessed at each vaccine shot (D0/D28) and 6 weeks after the 2nd dose(D69), only in individuals with negative baseline IgG/NAb and those who did not have coronavirus-19(COVID19) during follow-up. Vaccine safety was also assessed in all participants.
Results: Patients and controls had comparable median ages [48(38.5-57) vs 48(38-57) years, p= 0.945]. Patients had mostly diffuse SSc (68.6%) and the majority (74.5%) had interstitial lung disease. Most patients were under immunosuppressive therapy (72.5%), mainly mycophenolate mofetil (MMF) (52.9%). After full vaccination (D69), anti-SARS-CoV-2-IgG frequency (64.1% vs 94.2%, p< 0.001) and NAb positivity (53.8% vs 76.9%; p= 0.006) were moderate, although lower than controls. The first dose response (D28) was low and comparable for both SC (p= 0.958) and NAb positivity (p= 0.537). SSc patients under MMF monotherapy vs other (no therapy/other DMARDs) had lower immunogenicity (SC : 31.3% vs 90%, p< 0.001) and NAb : 18.8% vs 85%, p< 0.001). Multiple regression analysis confirmed that MMF use, but not disease subtype, is associated with insufficient seroconversion [odds ratio (OR)=0.056(95%CI 0.009-0.034), p= 0.002] and NAb positivity [OR = 0.047(95%CI 0.007-0.036), p= 0.002]. No moderate/severe side-effects were observed.
Conclusion: CoronaVac has an excellent safety profile and moderate response to anti-SARS-CoV-2 vaccine in SSc. Vaccine antibody response is not influenced by disease subtype and is greatly affected by MMF, reinforcing the need for additional strategies to up-modulate vaccine response in this subgroup of patients.
Trial registration: ClinicalTrials.gov, https://clinicaltrials.gov, NCT04754698.
Keywords: SARS-CoV-2; Systemic sclerosis; immunogenicity; mycophenolate; vaccine.
. 2021 Dec 11;keab886.
doi: 10.1093/rheumatology/keab886. Online ahead of print.
SARS-CoV-2 vaccine in patients with systemic sclerosis: Impact of disease subtype and therapy
Percival Degrava Sampaio-Barros[SUP] 1 [/SUP], Ana Cristina Medeiros-Ribeiro[SUP] 1 [/SUP], Ana Paula Luppino-Assad[SUP] 1 [/SUP], Renata Miossi[SUP] 1 [/SUP], Henrique Carriço da Silva[SUP] 1 [/SUP], Emily F V N Yuki[SUP] 1 [/SUP], Sandra G Pasoto[SUP] 1 [/SUP], Carla G S Saad[SUP] 1 [/SUP], Clóvis A Silva[SUP] 1 2 [/SUP], Léonard V K Kupa[SUP] 1 [/SUP], Giordano B H Deveza[SUP] 1 [/SUP], Tatiana N Pedrosa[SUP] 1 [/SUP], Nádia E Aikawa[SUP] 1 2 [/SUP], Eloisa Bonfá[SUP] 1 [/SUP]
Affiliations
- PMID: 34894235
- DOI: 10.1093/rheumatology/keab886
Abstract
Objective: To analyse the safety, immunogenicity and factors affecting antibody response to Severe Acute Respiratory Syndrome-Coronavirus-2(SARS-CoV-2) vaccination in patients with systemic sclerosis (SSc).
Methods: This is a phase 4 prospective study within a larger trial of two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in 51 SSc patients compared with 153 controls. Anti-SARS-CoV-2-IgG and neutralizing antibodies (NAb) were assessed at each vaccine shot (D0/D28) and 6 weeks after the 2nd dose(D69), only in individuals with negative baseline IgG/NAb and those who did not have coronavirus-19(COVID19) during follow-up. Vaccine safety was also assessed in all participants.
Results: Patients and controls had comparable median ages [48(38.5-57) vs 48(38-57) years, p= 0.945]. Patients had mostly diffuse SSc (68.6%) and the majority (74.5%) had interstitial lung disease. Most patients were under immunosuppressive therapy (72.5%), mainly mycophenolate mofetil (MMF) (52.9%). After full vaccination (D69), anti-SARS-CoV-2-IgG frequency (64.1% vs 94.2%, p< 0.001) and NAb positivity (53.8% vs 76.9%; p= 0.006) were moderate, although lower than controls. The first dose response (D28) was low and comparable for both SC (p= 0.958) and NAb positivity (p= 0.537). SSc patients under MMF monotherapy vs other (no therapy/other DMARDs) had lower immunogenicity (SC : 31.3% vs 90%, p< 0.001) and NAb : 18.8% vs 85%, p< 0.001). Multiple regression analysis confirmed that MMF use, but not disease subtype, is associated with insufficient seroconversion [odds ratio (OR)=0.056(95%CI 0.009-0.034), p= 0.002] and NAb positivity [OR = 0.047(95%CI 0.007-0.036), p= 0.002]. No moderate/severe side-effects were observed.
Conclusion: CoronaVac has an excellent safety profile and moderate response to anti-SARS-CoV-2 vaccine in SSc. Vaccine antibody response is not influenced by disease subtype and is greatly affected by MMF, reinforcing the need for additional strategies to up-modulate vaccine response in this subgroup of patients.
Trial registration: ClinicalTrials.gov, https://clinicaltrials.gov, NCT04754698.
Keywords: SARS-CoV-2; Systemic sclerosis; immunogenicity; mycophenolate; vaccine.